64
Participants
Start Date
February 28, 2007
Primary Completion Date
January 31, 2009
Study Completion Date
June 30, 2009
Placebo
Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Avatrombopag tablets
Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Mount Sinai Medical Center, New York
New York Presbyterian Hospital, Weill Medical College of Cornell University, New York
Western Pennsylvania Hospital, Pittsburgh
UPENN, Philadelphia
Johns Hopkins University, Baltimore
Emerywood Oncology and Hematology, High Point
Cancer Centers of the Carolina, Greenville
Columbus Clinic, PC, Columbus
Florida Cancer Institute, New Port Richey
Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center, Columbus
Cancer Care Center, Inc., New Albany
John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology, Chicago
Comprehensive Bleeding Disorders Center, Peoria
Kansas City Cancer Center, LLC, Kansas City
Capitol Comprehensive Cancer Care Clinic, Jefferson City
University of California Irvine Cancer Center, Orange
Pacific Coast Hematology/Oncology Medical Group Inc., Fountain Valley
Pacific Cancer Medical Center, Inc, Anaheim
Comprehensive Blood and Cancer Center, Bakersfield
Puget Sound Blood Center, Seattle
Bay Area Cancer Research Group, LLC, Concord
Georgetown University, Washington D.C.
Davis, Posteraro and Wasser, MDs, LLP, Manchester
Massachusetts General Hospital, Boston
UMDNJ - Robert Wood Johnson Medical School, New Brunswick
Eisai Inc.
INDUSTRY